Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
- None.
- None.
Insights
SGT-610's progression into phase 3 clinical trials represents a significant milestone in the treatment landscape for Gorlin Syndrome, a rare genetic condition that predisposes individuals to multiple basal cell carcinomas (BCC). Currently, the standard of care involves surgery and the use of oral hedgehog inhibitors, which can have systemic side effects due to their mode of administration. The development of a topical hedgehog inhibitor like SGT-610 could potentially offer a safer alternative by reducing systemic exposure.
Moreover, the designation of SGT-610 as an Orphan Drug underscores its importance, as this status is granted to treatments for diseases affecting fewer than 200,000 people in the U.S. and comes with benefits like tax credits and market exclusivity upon approval. The anticipation of trial results by the end of 2025 suggests a long-term investment horizon for stakeholders, with the potential for significant impact on Sol-Gel's stock performance if the results are positive and lead to FDA approval.
From a dermatological perspective, the innovation of SGT-610 lies in its mechanism of action. Hedgehog pathway inhibitors target the cellular signaling involved in the proliferation of BCC. A topical formulation like Patidegib gel, 2%, could minimize adverse effects seen with systemic treatments and improve patient compliance, especially important in chronic conditions like Gorlin Syndrome where long-term treatment is necessary.
Successful commercialization of SGT-610, in partnership with Galderma, could also enhance Sol-Gel's market position in dermatology, leveraging Galderma's established distribution and marketing capabilities. This strategic partnership might not only expedite market penetration upon approval but also strengthen investor confidence in Sol-Gel's ability to deliver on its pipeline.
Analyzing Sol-Gel's financial health, the company's announcement of maintaining a cash runway into the second half of 2025 is crucial. It suggests that the company has sufficient funds to complete the ongoing phase 3 trial without the immediate need for additional financing, which could dilute existing shareholders' stakes. However, investors should monitor the burn rate and potential capital raises in the future, especially as the company approaches the commercialization phase, which requires significant investment.
The partnership with Galderma to commercialize TWYNEO® and EPSOLAY® in the U.S. is also noteworthy. These products could provide a steady revenue stream to fund ongoing research and development activities. The financial results for the full year ended December 31st, 2023, would offer insights into the company's operational efficiency and the success of these commercialized products in contributing to the company's bottom line.
- An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened;
Results are expected by the end of 2025 - Sol-Gel maintains a cash runway into the second half of 2025
NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel,
2023 - Corporate Highlights and Recent Developments
- On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened. Sol-Gel acquired Patidegib from PellePharm Inc. and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients. SGT-610 is a new topical hedgehog inhibitor to prevent the new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. Sol-Gel is conducting a Phase-3 clinical trial to investigate SGT-610 in approximately 140 subjects at about 40 experienced clinical centers in North America, the United Kingdom, and Europe.
- On June 6, 2023, Sol-Gel and Searchlight Pharma Inc. announced licensing agreements to commercialize TWYNEO and EPSOLAY in Canada, according to which Sol-Gel is to receive up to
$11 million in upfront payments and regulatory and sales milestones for both drugs, combined plus additional royalties ranging from low double digits to high- teen. - On January 27, 2023, Sol-Gel announced the acquisition of topically applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome for PellePharm Inc., for an upfront payment of
$4.7 million , total development and NDA acceptance milestones of up to$6 million and based on the expected market potential up to$64 million in commercial milestones, as well as single digit royalties. Gorlin syndrome is a rare disease with no currently approved therapies by the U.S. Food and Drug Administration (FDA) or European Medical Association (EMA). Investigational compound SGT-610 has the potential to be the first-ever drug for the chronic prevention of BCCs in Gorlin syndrome patients if approved. - Over the full year of 2023, TWYNEO grew its total prescriptions, with cumulative annual total prescriptions exceeding 106,000 and total prescriptions in the fourth quarter exceeding 27,000, as reported by IQVIA. The number of prescribers also grew quarterly, with a
6% growth of new prescribers for the fourth quarter. The majority of scripts were written by TWYNEO’s high base of recurring prescribers, with fourth-quarter patient refills increasing by12% , driven by a targeted adherence campaign. In addition, TWYNEO increased its broad commercial formulary coverage, with over 6 million additional lives covered between December 2022 and December 2023 per MMIT Analytics. (*) - Over the full year of 2023, EPSOLAY also grew its total prescriptions every quarter, leading to cumulative annual total prescriptions of approximately 53,000 and total prescriptions in the fourth quarter exceeding 14,000, as reported by IQVIA. EPSOLAY also experienced quarterly growth in terms of the number of prescribers, with unique prescribers growing by
8% in the fourth quarter. Resulting from a targeted patient adherence campaign also for EPSOLAY, there was a significant increase in patient refills of34% in the quarter. Overall, EPSOLAY grew commercial formulary coverage annually by over 12 million covered or better lives, according to MMIT Analytics.
(*) MMIT - Managed Markets Insight & Technology
- Based on Sol-Gel's financing and adoption of cost-saving measures during 2023, the company continues to maintain its cash runway into the second half of 2025.
Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel, stated: "Sol-Gel is advancing the pivotal Phase 3 clinical trial with SGT-610 in accordance with the planned timelines and expects to have the results by the end of 2025. We estimate that the current trial protocol and its defined targets may facilitate the essential outcome, allowing Sol-Gel to provide Gorlin syndrome patients with the first drug that could prevent new BCCs, with a potential market estimated at more than
Financial Results for the Year Ended December 31st, 2023
We generated
Our research and development expenses were
Our general and administrative expenses were
Sol-Gel reported a net loss of
As of December 31, 2023, Sol-Gel had
About Gorlin Syndrome and SGT-610
SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for prevention of BCCs in Gorlin syndrome patients, if approved. Gorlin syndrome, an autosomal dominant genetic disorder affecting approximately 1 in 27,000-31,000 people in the U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1) gene. Normally, the PTCH1 gene blocks the smoothened, frizzle class receptor (SMO) gene, turning off the hedgehog signaling pathway when it is not needed. Mutations in the PTCH1 gene may cause a loss of PTCH1 function, release of SMO, and may allow BCC tumor cells to divide uncontrollably. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing or partnering drug products to treat skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris inadults and pediatric patients nine years of age and older; and Epsolay, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to and commercialized by Galderma in the US, and Searchlight in Canada.
The Company’s pipeline also includes Phase 3 clinical trial of Orphan and breakthrough drug candidate SGT-610, which is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment of rare hyperkeratinization disorders.
For additional information, please visit our new website: www.sol-gel.com
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, the potential market of SGT-610, SGT-610 potential as the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, SGT-610 improved safety profile compared to oral hedgehog inhibitors, timing of completing the Phase 3 clinical trial of SGT-610, number of subjects and clinical centers in the Phase 3 clinical trial of SGT-610, success of any clinical studies, and obtaining regulatory approval for our product candidates including SGT-610; our expected cash runway; our ability to out-license additional international rights for TWYNEO and EPSOLAY; and the commercial acceptance and profitability of TWYNEO and EPSOLAY. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management’s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, a delay in the timing of our clinical trials, including the timing of completing the Phase 3 clinical trial of SGT-610, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators’ ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators’ ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators’ ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving Israel with other parties. These factors, and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 10, 2023, as amended, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Source: Sol-Gel Technologies Ltd.
| SOL-GEL TECHNOLOGIES LTD. | |||||
| CONSOLIDATED BALANCE SHEETS | |||||
| (U.S. dollars in thousands, except share and per share data) | |||||
| December 31 | |||||
| 2022 | 2023 | ||||
| Assets | |||||
| CURRENT ASSETS: | |||||
| Cash and cash equivalents | $ | 12,448 | $ | 7,513 | |
| Bank deposits | 12,500 | 10,012 | |||
| Marketable securities | 8,678 | 20,471 | |||
| Accounts receivables | 62 | 377 | |||
| Receivables from collaborative arrangements | 7,858 | - | |||
| Prepaid expenses and other current assets | 1,509 | 2,794 | |||
| TOTAL CURRENT ASSETS | 43,055 | 41,167 | |||
| NON-CURRENT ASSETS: | |||||
| Restricted long-term deposits and cash equivalents | 1,288 | 1,284 | |||
| Property and equipment, net | 660 | 434 | |||
| Operating lease right-of-use assets | 876 | 1,721 | |||
| Other long-term assets | - | 55 | |||
| Funds in respect of employee rights upon retirement | 749 | 626 | |||
| TOTAL NON-CURRENT ASSETS | 3,573 | 4,120 | |||
| TOTAL ASSETS | $ | 46,628 | $ | 45,287 | |
| Liabilities and shareholders' equity | |||||
| CURRENT LIABILITIES: | |||||
| Accounts payable | $ | 251 | $ | 154 | |
| Other accounts payable | 2,360 | 3,921 | |||
| Current maturities of operating leases | 718 | 447 | |||
| TOTAL CURRENT LIABILITIES | 3,329 | 4,522 | |||
| LONG-TERM LIABILITIES: | |||||
| Operating leases liabilities | 54 | 1,206 | |||
| Liability for employee rights upon retirement | 1,032 | 915 | |||
| TOTAL LONG-TERM LIABILITIES | 1,086 | 2,121 | |||
| TOTAL LIABILITIES | 4,415 | 6,643 | |||
| COMMITMENTS (Note 7) | |||||
| SHAREHOLDERS' EQUITY: | |||||
| Ordinary shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2022 and 2023, respectively; issued and outstanding: 23,129,469 and 27,857,620 as of December 31, 2022 and December 31, 2023, respectively | 638 | 774 | |||
| Additional paid-in capital | 234,640 | 258,173 | |||
| Accumulated deficit | (193,065) | (220,303) | |||
| TOTAL SHAREHOLDERS' EQUITY | 42,213 | 38,644 | |||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 46,628 | $ | 45,287 | |
| SOL-GEL TECHNOLOGIES LTD. | |||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
| (U.S. dollars in thousands, except share and per share Data) | |||||
| Year ended December 31, | |||||
| 2021 | 2022 | 2023 | |||
| COLLABORATION REVENUES | 23,772 | - | - | ||
| LICENSE REVENUES | 7,500 | 3,883 | 1,554 | ||
| TOTAL REVENUES | 31,272 | 3,883 | 1,554 | ||
| RESEARCH AND DEVELOPMENT EXPENSES | 20,381 | 12,682 | 23,541 | ||
| GENERAL AND ADMINISTRATIVE EXPENSES | 8,451 | 7,445 | 7,373 | ||
| OTHER INCOME, net | 524 | - | 55 | ||
| TOTAL OPERATING INCOME (LOSS) | 2,964 | (16,244) | (29,305) | ||
| FINANCIAL INCOME, net | 257 | 1,321 | 2,067 | ||
| NET INCOME (LOSS) FOR THE YEAR | 3,221 | (14,923) | (27,238) | ||
| BASIC EARNINGS (LOSS) PER ORDINARY SHARE | 0.14 | (0.65) | (1.01) | ||
| DILUTED EARNINGS (LOSS) PER ORDINARY SHARE | 0.14 | (0.65) | (1.01) | ||
| WEIGHTED AVERAGE NUMBER OF SHARES | |||||
| OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED EARNINGS (LOSS) PER SHARE: | |||||
| BASIC | 23,063,493 | 23,128,722 | 27,087,081 | ||
| DILUTED | 23,566,182 | 23,128,722 | 27,087,081 | ||
FAQ
What is the status of Sol-Gel's phase 3 clinical trial for Gorlin Syndrome with SGT-610?
Which company has Sol-Gel partnered with for commercialization of dermatology products in the U.S.?
What is the potential of SGT-610 in preventing new basal cell carcinomas in Gorlin syndrome patients?
What is the expected safety profile of SGT-610 compared to oral hedgehog inhibitors?
How many subjects are involved in Sol-Gel's Phase-3 clinical trial for SGT-610?
